8-K: Current report filing
Published on August 12, 2009
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): August 10,
2009
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
|
000-51476
|
20-2903526
|
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification
No.)
|
|
248 Route 25A, No. 2, East Setauket, New
York
|
11733
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
631-942-7959
(Registrant’s
Telephone Number, Including Area Code)
|
Item
1.01
|
Entry
into a Material Agreement
|
Effective
August 10, 2009, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into
Amendment No. 6 to the Cooperative Research and Development Agreement (“CRADA”)
with the National Institute of Neurological Disorders and Stroke of the National
Institutes of Health pursuant to which the term of the CRADA was extended from
September 30, 2009 through September 30, 2011. Pursuant to the
amendment, the Company has agreed to aggregate payments of $100,000 in two
installments of $50,000 each payable on October 1, 2010 and January 5, 2011,
inclusive of any prior unpaid commitments.
|
Item
9.01
|
Financial
Statements and Exhibit
|
(d) Exhibits
|
Exhibit
10.1
|
Amendment
6 to CRADA
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
|||
|
Date: August
12, 2009
|
By:
|
/s/ John S. Kovach | |
| John S. Kovach, Chairman of the Board and Chief Executive Officer (principal executive officer |
|||
3